Luitpold Animal Health brings Adequan products back to market after shortage

Adequan Canine, an arthritis drug that has been difficult for consumers to find lately, will return to the market in late August following the temporary supply interruption.

The FDA released an update on the shortage after reportedly being contacted by many consumers who were concerned about the shortage. 

According to maker Luitpold Animal Health, Adequan was unavailable due to the company renovating and upgrading its manufacturing facility in Shirley, New York, which affected the company's manufacturing capabilities. 

Luitpold originally planned to re-release Adequan products in the first part of 2014, but the company worked closely with the FDA to move that target date up to late August 2013, the company said.

The manufacturer recommends that concerned parties visit their dedicated Adequan page or call its customer service department at 1-800-458-0163.

Adequan Canine is the only polysulfated glycosaminoglycan (PSGAG) approved by the FDA for controlling signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints, according to Luipold.

Also returning to the market are Adequan IM and Adequan IA, which treat non-infectious degenerative and/or traumatic joint dysfunction and associated lameness in horses.